close
Add to watchlist
Nile Therapeutics Inc (NLTX)
Nile Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for the treatment of cardiovascular disease and other areas of unmet medical needs. The company focuses on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. CD-NP was designed to reduce symptoms of dyspnea in heart failure patients through both a reduction in intracardiac pressure and an improvement in renal function. Nile is also developing CU-NP, a novel, rationally designed natriuretic peptide. The company was founded in 2005 and is based in San Francisco, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 9999.99 |
| Volume | 130698 |
| Volume Avg | (mio) 1065.52 |
| 52 Week High | 0.29 |
| 52 Week Low | 0.00 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | 0.00 |
| EPS change Q/Q | -60% |
| EPS change Q/Q Yr ago | -66.67% |
| EPS change Q/Q next Q est | 100% |
| EPS change Y/Y | -63.16% |
| REV change Q/Q | 0% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | 0.00 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |